Tag Archives: New York

Hospital Mergers: The Future of COPA Immunity

Photo of Carl HittingerPhoto of Marc SchildkrautPhoto of Tyson HerroldBy Carl Hittinger, Marc Schildkraut and Tyson Herrold on Posted in FTC
In October 2022, the Federal Trade Commission issued a Public Comment opposing a Certificate of Public Advantage (COPA) for the merger of State University of New York Upstate Medical University (SUNY Upstate) and Crouse Health System, Inc. The FTC’s Public Comment advises the New York State Department of Health that the merger would harm competition, … Continue Reading

Turing Pharmaceuticals Facing NY Antitrust Inquiry in Wake of 5,000 Percent Price Hike

Photo of Julian PerlmanBy Julian Perlman on Posted in Antitrust Litigation, Healthcare
Turing Pharmaceuticals is back in the news over its marketing and distribution of Daraprim, the anti-parasitic drug crucial for treating toxoplasmosis, which can be fatal to patients with compromised immune systems. As you have probably read by now, Turing recently acquired the rights to Daraprim and thereafter announced its intention to raise the cost of … Continue Reading
LexBlog